RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New In-Body CAR-T therapy takes on Hard-to-Treat myeloma
Disease control Not yet recruitingThis early study tests a new treatment called IASO206 for people with multiple myeloma that has come back or stopped responding to other therapies. The treatment uses a special type of cell therapy that works inside the body to attack cancer cells. The main goals are to check if …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 09:04 UTC
-
New combo therapy aims to boost myeloma remission
Disease control Not yet recruitingThis early-phase trial tests whether giving a bispecific antibody drug before CAR-T cell therapy can improve outcomes for people with relapsed/refractory multiple myeloma, a blood cancer that has stopped responding to standard treatments. About 20 adults will receive the antibody…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 09:00 UTC
-
New combo attack: antibody bridge before CAR-T for myeloma
Disease control Not yet recruitingThis early-phase study tests whether giving a bispecific antibody (CM336) before CAR-T cell therapy can improve outcomes for people with relapsed or refractory multiple myeloma. Ten participants will receive the antibody as a "bridge" to control the cancer before the main CAR-T i…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 08:58 UTC
-
New CAR-T therapy targets Hard-to-Treat multiple myeloma in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called IASO104 for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 08:55 UTC